Pembrolizumab, marketed under the brand name Keytruda, is a type of immunotherapy known as a checkpoint inhibitor. It works by targeting the PD-1 pathway, a protein on T cells that normally helps keep these cells from attacking other cells in the body. By blocking this pathway, pembrolizumab helps the immune system to recognize and destroy cancer cells.
